Christopher Gibson - 17 Nov 2025 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Executive Officer, Director
Signature
/s/ Kyle Nelson, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
17 Nov 2025
Transactions value $
-$333,615
Form type
4
Date filed
19 Nov 2025, 19:37
Previous filing
06 Nov 2025
Next filing
05 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gibson Christopher Chief Executive Officer, Director C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY /s/ Kyle Nelson, attorney-in-fact 2025-11-19 0001856369

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Tax liability -$167K -40.4K -4.23% $4.14 914K 17 Nov 2025 Direct F1
transaction RXRX Class A Common Stock Conversion of derivative security $0 +40K +4.38% $0.00 954K 19 Nov 2025 Direct F2, F3
transaction RXRX Class A Common Stock Sale -$166K -40K -4.19% $4.16 914K 19 Nov 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Class B Common Stock Conversion of derivative security $0 -40K -0.82% $0.00 4.82M 19 Nov 2025 Class A Common Stock 40K $0.00 Direct F2, F3
holding RXRX Class B Common Stock 386K 17 Nov 2025 Class A Common Stock 0 $0.00 by LAHWRAN-3 LLC F3, F4
holding RXRX Class B Common Stock 388K 17 Nov 2025 Class A Common Stock 0 $0.00 by LAHWRAN-4 LLC F3, F5
holding RXRX Class B Common Stock 50K 17 Nov 2025 Class A Common Stock 0 $0.00 by Gibson Family Trust F3, F6
holding RXRX Stock Option (Right to Buy) 667K 17 Nov 2025 Class A Common Stock 0 $10.09 Direct F7
holding RXRX Stock Option (Right to Buy) 1.05M 17 Nov 2025 Class A Common Stock 0 $7.25 Direct F8
holding RXRX Stock Option (Right to Buy) 814K 17 Nov 2025 Class A Common Stock 0 $8.55 Direct F9
holding RXRX Stock Option (Right to Buy) 399K 17 Nov 2025 Class A Common Stock 0 $11.40 Direct F10
holding RXRX Stock Option (Right to Buy) 5.44K 17 Nov 2025 Class A Common Stock 0 $11.40 Direct
holding RXRX Stock Option (Right to Buy) 283K 17 Nov 2025 Class A Common Stock 0 $2.48 Direct F11
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F2 This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 12, 2025.
F3 Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F4 The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
F5 The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
F6 The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.
F7 The option vests as to one forty-eighth (1/48th) of the original 666,898 shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F8 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2025, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F9 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F10 The option, originally for 416,350 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
F11 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.